The board of directors for AlzeCure Pharma AB, a company listed on Nasdaq First North Premier Growth Market, has resolved on a rights issue of approximately SEK 31.7 million. In addition, the board may exercise an over-allotment option of up to SEK 15.0 million. The rights issue is subject to approval of the general meeting of shareholders.
Synch Advokat is the legal advisor to AlzeCure Pharma in the transaction. Erik Penser Bank is the financial advisor.
Synch’s team consists of Mattias Anjou, Louise Berlin and Olof Hultén.
Synch offers legal services in four business areas – Advisory Services, Project & Transactional Services, Managed Services, and Digital Services
